Semalutide, glucagon senge peptide (GLP-1) receptor agonist, yakabvumidzwa kurapwa kwerudzi rwechipiri chirwere cheshuga. Somaglutide yakagadzirwa naNovo Nordisk mu2012 senzira yenguva refu kune Liraglutide. Kuenzaniswa neLiraglutide nemimwe mishonga yeDiabetes, imwe yemabhenefiti eSomaglutide ndeyekuti ine nguva yakareba yekuita, saka kamwe chete pasvondo jekiseni rinokwana. Muna Zvita 2017, iyo US Chikafu neDrug Administration (FDA) yakabvumidza jekiseni remhando yesomalutide. Chikamu chechipiri chekuongorora kwekliniki yakawana kuti Somaglutide yakaderedza uremu hwevarwere vechirwere cheshuga 2 uye vanhu vakafuta, uye kuora muviri kwaionekwa sechikonzero chekuderedza kushandiswa kwesimba kunokonzerwa nekuderedza kudya.
